EyePoint Pharmaceuticals, Inc. (EYPT) AI Stock Analysis

Headquartered in Watertown, Massachusetts, EyePoint Pharmaceuticals, Inc. develops and commercializes treatments for severe ophthalmic conditions. Founded in 2000 as pSivida Corp. and rebranded in March 2018, the company employs 214 people. Its commercial offerings include YUTIQ for chronic non-infectious uveitis affecting the posterior segment of the eye and DEXYCU for postoperative inflammation. At the center of its development platform is Durasert technology, which enables sustained intraocular drug delivery. Leveraging this proprietary system, the company is advancing its lead investigational candidate, EYP-1901, through Phase 2 clinical trials.

Annual revenue contracted from $46.0M in FY2023 to $43.3M in FY2024 and $31.4M in FY2025, reflecting a 27.5% decline in FY2025. Over the 5-year period from FY2020 to FY2025, revenue delivered a CAGR of -1.8%. Despite gross margin improving to 93.4% in FY2025, operating margin declined to -776.0% as R&D expenses expanded to $221.0M. Net income reached -$232.0M in FY2025, resulting in diluted EPS of -$3.16. For the trailing twelve months ended June 30, 2026, revenue totaled $2.8M, with quarterly revenue falling 90.5% year-over-year and trailing twelve month EPS at -$3.75.

As of June 30, 2026, EyePoint Pharmaceuticals held $180.5M in cash and short-term investments against total debt of $22.4M, resulting in net cash of $158.1M. The company maintains a current ratio of 4.50 and a debt-to-equity ratio of 0.13, supported by $166.4M in shareholders' equity. In FY2025, operating cash flow stood at -$240.1M and free cash flow was -$243.4M, with capital expenditures of $3.3M. Over the past five years, the share count expanded by 164.7%.

EyePoint Pharmaceuticals trades at an enterprise value of $160.1M and a market capitalization of $250.7M. The stock trades at a price-to-sales multiple of 89.9x and an EV-to-revenue multiple of 57.4x, both well above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its forward P/E of 6.2x trades below the peer group median of 17.3x, while its EV-to-EBITDA ratio of 11.6x aligns near the peer median of 12.0x. Over the past year, EYPT declined 74.1%, trailing the S&P 500 (SPY) return of 16.8%.

Wall Street analysts cover EyePoint Pharmaceuticals with 6 Strong Buy, 1 Buy, and 6 Hold ratings, with 0 Sell ratings. The mean price target is $25.91, representing upside of 766.5% compared to the last close of $2.99 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.7M and EPS of -$3.64. For the next fiscal year, 11 analysts project revenue to reach $17.9M. The company recorded 0 EPS beats over the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of EyePoint Pharmaceuticals, Inc. (EYPT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EYPT income statement, EYPT balance sheet, EYPT key metrics, EYPT analyst forecast, EYPT chart. See the EYPT stock overview for the latest quote and news.